Search

1. I first looked up travel to and from Liberia during the Ebola outbreak, since it had been seized. There was a ban, which has since been lifted after, but people coming to and from West Africa are still screened and recommended to visit physicians. As of mid-2015 there wa still a 21 day monitoring period needed. http://www.infectioncontroltoday.com/news/2015/05/cdc-downgrades-travel…'
2. I was interested if there had been any progress on treatment for Ebola, but found that the main form of treatment is supportive care. Doctors are informed to provide IV fluid and ensure that the patient's immune response and other bodily functions are functioning properly. A vaccine is being worked on but has not gone through a trial to prove safety and effectiveness. https://www.cdc.gov/vhf/ebola/treatment/index.html
3. I looked further into the vaccine being produced for Ebola. Currently, there is a combined phase 2 and phase 3 trial occurring in Sierra Leone called STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola). The study is unblinded, so patients know whether or not they have received the vaccine. The vaccine is a rVSV-ZEBOV, or recombinant Vesicular Stomatitis Virus Zaire ebolavirus vaccine. This vaccine is also being used in phase 2 and phase 3 trials in Guinea and Liberia http://www.cdc.gov/vhf/ebola/strive/qa.html

The article's bibliography contains many references including the WHO, the Red Cross, and other organizations, as well as many other experts and professionals in the field. 

The federal government funds OSHA.

The convention in 1951 was a response to WW2 and the vast amounts of refugees that existed as a result. States involved in the convention and the UN could decide to apply it to refugees not necessarily from WW2, but in 1967, the limits were removed and made it so that it could apply to any refugees, not just those from WW2. It has since been used during major refugee crises in Africa, the Middle East, and Asia. 

This program is located at Tulane University in New Orleans, but has partnership with Ethiopia, Ghana, Mali, Nigeria, Somalia, South Africa, Sri Lanka, Thailand, Uganda, and the US. 

The author of this article did a lot of interviews of locals and officials in the area as a means of obtaining information. Research was also drawn from other online sources. 

REMM (Radiation Emergency Medical Management) is produced by US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, the National Library of Medicine, the National Cancer Institute, and the Centers for Disease Control and Prevention. 

According to Google Scholar, this article has been cited 85 times. This is a pretty large amount of citations, which are primarily articles regarding societal effects of distress and disasters. 

The article is published in the Japanese Journal of Clinical Oncology. It is meant for clinical oncologists and publishes articles on medical oncology, clinical trials, radiology, surgery, basic research, epidemiology, and palliative care. It was established in 1971 and is the first journal from Japan to publish clinical research on cancer in English. Since 1977, JJCO is a sister-journal to the Journal of the National Cancer Institute and is linked through Oxford Journals.